Harpoon Therapeutics Inc. (NASDAQ:HARP) Relative Strength Index (RSI) is 55.33, with weekly volatility at 6.21% and ATR at 1.59. The HARP stock’s 52-week price range has touched low of $10.27 and a $25.24 high. Intraday shares traded counted 0.12 million, which was 55.79% higher than its 30-day average trading volume of 262.74K. Its shares traded lower over the last trading session, losing -2.44% on 02/11/21. The shares fell to a low of $20.0701 before closing at $20.77. HARP’s previous close was $21.29 while the outstanding shares total 25.08M. The firm
Investors have identified the Biotechnology company Harpoon Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $667.96 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Harpoon Therapeutics Inc. (HARP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 157.72 million total, with 45.21 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -2.15 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on HARP sounds very interesting.
Is the stock of HARP attractive?
In related news, 10% Owner, MPM BioVentures 2014, L.P. sold 9,400 shares of the company’s stock in a transaction that recorded on Feb 09. The sale was performed at an average price of 20.25, for a total value of 190,350. As the sale deal closes, the 10% Owner, MPM BioVentures 2014, L.P. now sold 72,128 shares of the company’s stock, valued at 1,445,445. Also, 10% Owner, MPM BioVentures 2014, L.P. sold 10,172 shares of the company’s stock in a deal that was recorded on Feb 05. The shares were price at an average price of 20.01 per share, with a total market value of 203,542. Following this completion of acquisition, the 10% Owner, MPM BioVentures 2014, L.P. now holds 29,730 shares of the company’s stock, valued at 605,600. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.30%.
8 out of 9 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Harpoon Therapeutics Inc.. 0 analysts has assigned a Sell rating on the HARP stock. The 12-month mean consensus price target for the company’s shares has been set at $31.89.